Tuberous sclerosis, or Bourneville disease, is a rare genetic disorder characterized by the development of benign tumors (hamartomas) in various organs, including the brain, kidneys, heart, lungs, and skin. The disease is associated with mutations in the TSC1 and TSC2 genes, which encode proteins that regulate cell growth and differentiation. Disruption of these genes leads to uncontrolled cell growth and the formation of hamartomas, which can cause serious clinical manifestations such as seizures, mental retardation, autism, developmental delay, and organ damage. Tuberous sclerosis is a multisystem disorder that can manifest differently in different patients, ranging from mild forms to severe complications.
History of the disease and interesting historical facts
Tuberous sclerosis was first described in 1880 by the French neurologist Désiré-Magloire Bourneville, who noted the combination of epilepsy, skin lesions and mental retardation in his patients. Later, in the early 20th century, pathologists discovered that the disease was associated with the formation of tubers (thickenings) in the cerebral cortex, which gave the disease its name. The discovery of the TSC1 and TSC2 genes in the 1990s led to important advances in understanding the molecular mechanisms of the disease and the development of targeted therapies, such as mTOR inhibitors, which have significantly improved the prognosis for patients with the disease.
Epidemiology
Tuberous sclerosis occurs with a frequency of 1 in 6,000–10,000 live births, making it a relatively rare disease. The disease occurs in both sexes with equal frequency and does not depend on ethnicity. Most cases (about 70%) are associated with new spontaneous mutations in the TSC1 or TSC2 genes, and only 30% are inherited in an autosomal dominant manner. Due to improved diagnostics and increased life expectancy of patients, the incidence of the disease is gradually increasing.
Genetic predisposition to this disease
Tuberous sclerosis is caused by mutations in the TSC1 genes (chromosome 9) and TSC2 (chromosome 16), which encode the proteins hamartin and tuberin, respectively. These proteins play a key role in inhibiting cell growth by regulating the mTOR pathway. Hamartin and tuberin normally interact to suppress mTOR activity, which limits cell proliferation. Mutations in these genes disrupt this process, leading to uncontrolled cell growth and the formation of hamartomas. An important feature of the disease is the possibility of mosaicism - when the mutation is present only in some cells of the body, which can lead to a variable clinical picture.
Risk factors for the development of this disease
The main risk factor for developing tuberous sclerosis is the presence of a mutation in one of the TSC1 or TSC2 genes. The risk is higher if one of the parents suffers from this disease, since the disease is inherited in an autosomal dominant manner, which means that the probability of passing on the mutation to offspring is 50%. Spontaneous mutations account for the majority of cases, and the factors influencing the occurrence of these mutations are not fully understood. To date, no influence of external factors such as infections or environmental exposure has been identified on the risk of developing tuberous sclerosis.
Diagnosis of this disease
The diagnosis of tuberous sclerosis is based on clinical features, genetic testing, and imaging studies. The main symptoms of the disease include:
— Epileptic seizures (observed in 80% patients).
- Mental retardation and developmental delay.
— Skin lesions (angiofibromas of the face, hypomelanotic spots).
— Kidney damage (angiomyolipomas).
- Heart damage (rhabdomyomas).
— Lung damage (lymphangioleiomatosis).
Laboratory methods include molecular genetic testing to detect mutations in the TSC1 and TSC2 genes. Radiological diagnostics, including MRI and CT of the brain, help identify tubercles and hamartomas, as well as assess the extent of damage to internal organs. Differential diagnosis is carried out with other diseases that can cause epileptic seizures and skin lesions, such as neurofibromatosis.
Treatment
Treatment of tuberous sclerosis is aimed at controlling symptoms and preventing complications, as there is no specific therapy that eliminates the cause of the disease. The main treatment methods include:
— Control of epilepsy with antiepileptic drugs (valproic acid, levetiracetam, topiramate).
— Use of mTOR inhibitors (sirolimus, everolimus), which inhibit cell growth and can reduce the size of hamartomas and angiomyolipomas.
— Surgical treatment in case of severe complications, such as large kidney or heart tumors that threaten the patient’s life.
- Symptomatic treatment of skin lesions using laser therapy or other cosmetic procedures.
Patients with tuberous sclerosis require a multidisciplinary approach to treatment, including the participation of neurologists, dermatologists, nephrologists and cardiologists.
List of medications used to treat this disease
— Everolimus is an mTOR inhibitor used to shrink tumors in tuberous sclerosis.
— Sirolimus is a similar drug that also targets mTOR activity.
— Valproic acid is an antiepileptic drug used to control seizures.
- Levetiracetam is an antiepileptic drug.
— Topiramate is another drug for the treatment of epilepsy, used in tuberous sclerosis.
Disease monitoring
Patients with tuberous sclerosis require regular monitoring to detect complications and adjust treatment in a timely manner. Important monitoring steps include:
— Regular MRI and CT scans to assess the condition of the brain, kidneys and lungs.
— Electroencephalography to monitor epileptic activity.
— Assessment of the condition of the heart and blood vessels, especially in children.
— Monitoring the child’s development and cognitive functions.
The prognosis depends on the degree of damage to various organs. In most cases, early treatment improves the patient's quality of life and prevents serious complications.
Age-related features of the disease
Tuberous sclerosis manifests at various ages, although most patients begin to show symptoms in childhood. Seizures usually begin in early childhood, often in the first years of life. Skin lesions and developmental delays also become noticeable in childhood. In adults, the disease may be less aggressive, but progressive damage to internal organs such as the kidneys and lungs may occur, requiring constant monitoring. Older patients may develop complications associated with the long-term course of the disease, such as kidney failure or heart problems.
Questions and Answers
- What is tuberous sclerosis? It is a rare genetic disorder characterized by the development of benign tumors in various organs, including the brain, kidneys and skin.
- What are the symptoms of tuberous sclerosis? The main symptoms include epileptic seizures, mental retardation, skin lesions and damage to internal organs.
- How is tuberous sclerosis transmitted? The disease is inherited in an autosomal dominant manner, but in most cases it is caused by spontaneous mutations.
- Are there treatments for tuberous sclerosis?
